With India being the diabetes capital of the world, the entry of a globally trusted GLP-1 therapy brings: Better glycaemic control Proven cardiovascular benefits Once-weekly dosing convenience A new benchmark in patient-centric diabetes care This launch is not just about a drug its about reshaping treatment outcomes, improving adherence, and elevating quality of life for millions of patients
Astaxanthin is renowned for its potent antioxidant and anti-inflammatory properties
This documentation also proves valuable when discussing injection issues with healthcare providers
Initial weight loss with GLP-1 receptor agonists typically becomes noticeable within the first 48 weeks of treatment, though the timeline varies considerably between individuals
GlobalData projects retatrutide could reach $15.6 billion in sales by 2031
Actual costs may be lower, depending on health insurance, discounts, assistance programs, and other factors